Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FY22X
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,284
Award facts
- Contract value 100% obligated
- $9,284.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,284.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a targeted procurement of a biologic medication used primarily in the treatment of moderate-to-severe allergic asthma and chronic idiopathic urticaria. The award was issued without a set-aside designation, leveraging open competition within the federal marketplace.
This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.9 billion contract vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies for military healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently delivering branded and generic prescription drugs, biologics, and specialty medications to Department of Defense healthcare sites across the nation. The company's woman-owned small business status has enabled it to compete effectively in federal procurement markets while maintaining a robust portfolio of pharmaceutical product deliveries to DLA.
Quick answers
Who was awarded contract SPE2DB25FY22X?
SPE2DB25FY22X was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 2, 2025.
How much is contract SPE2DB25FY22X worth?
The government has obligated $9,284 on SPE2DB25FY22X.
Is contract SPE2DB25FY22X an order under another contract?
Yes. SPE2DB25FY22X is a delivery order under SPE2DB22D9362, an indefinite delivery contract.
Was contract SPE2DB25FY22X competed?
The extent of competition for SPE2DB25FY22X was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award